Claims for Patent: 11,918,623

Summary for Patent: 11,918,623

Title:	GIP/GLP1 agonist compositions
Abstract:	A composition of tirzepatide, comprising an agent selected from NaCl and propylene glycol; and dibasic sodium phosphate is provided.
Inventor(s):	Vincent John Corvari, Christopher Sears Minie, Dinesh Shyamdeo Mishra, Ken Kangyi Qian
Assignee:	Eli Lilly and Co
Application Number:	US17/741,067
Patent Claims:	1. A method of treating obesity comprising administering to a human in need thereof an effective dose of a pharmaceutical composition comprising tirzepatide, or pharmaceutically acceptable salt thereof, wherein the tirzepatide concentration is from about 5 mg/mL to about 30 mg/mL; dibasic sodium phosphate is from about 0.67 to about 2.68 mg/mL; NaCl at a concentration from about 6.2 mg/mL to about 9.5 mg/mL; and optionally comprising from about 3.0 mg/mL to about 7.0 mg/mL phenol. 2. A method of treating obesity as claimed by claim 1 wherein the dose is administered using an automatic injection apparatus. 3. A method of treating obesity as claimed by claim 2 wherein the dose is administered once weekly. 4. A method of treating obesity comprising administering to a human in need thereof an effective dose of a pharmaceutical composition comprising tirzepatide, or a pharmaceutically acceptable salt thereof; NaCl at a concentration from about 6.2 mg/mL to about 9.5 mg/mL; and dibasic sodium phosphate. 5. A method as claimed by claim 4, wherein the tirzepatide, or a pharmaceutically acceptable salt thereof, concentration is from about 5 mg/mL to about 30 mg/mL. 6. A method as claimed by claim 5 wherein the dibasic sodium phosphate concentration is from about 1 mg/mL to about 3 mg/mL. 7. A method as claimed by claim 4 wherein the dibasic sodium phosphate concentration is from about 0.67 mg/mL to about 2.68 mg/mL. 8. A method as claimed by claim 7 wherein the dibasic sodium phosphate concentration is about 1.34 mg/mL. 9. A method as claimed by claim 8 wherein the tirzepatide, or a pharmaceutically acceptable salt thereof, concentration is selected from the group consisting of 5, 10, 15, 20, 25, and 30 mg/mL. 10. A method as claimed by claim 9 wherein the NaCl concentration is from about 7.0 mg/mL to about 9.0 mg/mL. 11. A method as claimed by claim 10 wherein the NaCl concentration is about 8.2 mg/mL. 12. A method as claimed by claim 1 wherein the tirzepatide, or a pharmaceutically acceptable salt thereof, concentration is selected from the group consisting of 5, 10, 15, 20, 25, and 30 mg/mL. 13. A method as claimed by claim 12 wherein the NaCl concentration is from about 7.0 mg/mL to about 9.0 mg/mL. 14. A method as claimed by claim 13 wherein the NaCl concentration is about 8.2 mg/mL. 15. A method of treating obesity comprising administering to a human in need thereof an effective dose of a pharmaceutical composition comprising: (a) tirzepatide, or pharmaceutically acceptable salt thereof, wherein the tirzepatide concentration is from about 5 mg/mL to about 30 mg/mL; (b) dibasic sodium phosphate, wherein the dibasic sodium phosphate concentration is about 1.34 mg/mL; and (c) NaCl, wherein the NaCl concentration is about 8.2 mg/mL; and wherein the dose is administered using an automatic injection apparatus.